Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2023 · 10-Q
Revenue$632.12M$632.12M−7.1% vs Q3 2022 Net Income$106.30M$106.30MN/M vs Q3 2022 EPS Diluted$3.64$3.64N/M vs Q3 2022 Gross Profit$335,700,000−9.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$97,711,000+786.1% Free Cash Flowderived$53,640,000N/M Margins · derivedGross margin53.1%−1.6 pt vs Q3 2022
Operating margin14.4%+0.5 pt vs Q3 2022
Net margin16.8%+40.7 pt vs Q3 2022
ended Sep 30, 2023 · filed Oct 27, 2023 · 27 d after period end